Behavioral Sciences
May 14, 2026
Fabiola Raffone, Carlo Ignazio Cattaneo, Enrico Pessina et al.
Trauma-related autobiographical memories can manifest as involuntary, vivid, emotionally charged intrusions that perpetuate avoidance, negative emotions, and functional impairment. While these memories are central to post-traumatic stress disorder (PTSD), they also occur across diagnoses and are often reported in depressive disorders, including treatment-resistant depression (TRD). Although...
Journal of Affective Disorders
May 14, 2026
Joshua Curtiss, Laya Dasari, Julianne Origlio et al.
Major Depressive Disorder (MDD) affects millions globally, with approximately 30% of patients experiencing treatment-resistant depression (TRD). While ketamine has emerged as a rapid-acting intervention, response rates remain variable, underscoring the need to refine precision medicine approaches for ketamine treatment. Network theories of mental health disorders have been promoted as framework...
Fortschritte der Neurologie · Psychiatrie
May 13, 2026
Cornelius Schüle, Anna Sobieraj, Helena Rogg
1 citation
Abstract: Esketamine is an NMDA receptor antagonist and was approved as a nasal spray in March 2019, initially in the USA and then in December 2019 in Europe, as an adjunct to antidepressant pharmacotherapy for the treatment of treatment-resistant major depression or for rapid symptom reduction in psychiatric emergency situations in patients with major depression. In addition, esketamine nasal...
Suchttherapie
May 12, 2026
Louise Penzenstadler, Tatiana Aboulafia Brakha, Daniele Zullino
Zusammenfassung Substanzkonsumstörungen (SUD) sind chronische Erkrankungen mit hohen Rückfallraten und begrenzter Wirksamkeit etablierter Behandlungen. Vor diesem Hintergrund rückt die psychedelisch-assistierte Psychotherapie (PAP) mit Psilocybin und LSD zunehmend in den Fokus; die Literatur berichtet Hinweise auf mögliche Effekte insbesondere bei AUD und affektiven Symptomen. Ziel der Studie:...
Journal of Pre-Clinical and Clinical Research
May 12, 2026
Bartłomiej Kosiarski, A. Skrzypek, Patrycja Markowicz et al.
Rapid-acting interventions in treatment-resistant depression – a comparative review of
Frontiers in Psychology
May 12, 2026
Xi Zhang, Hongyan Wang, Xiaohui Wang et al.
Objective To evaluate the efficacy of MBI on depression among family caregivers of dementia patients, and to analyze the impact of intervention duration, follow-up period, and intervention methods on treatment outcomes. Methods Search Embase, The Cochrane Library, CINAHL, PubMed, SinoMed, CNKI, Wanfang, and VIP databases for randomized controlled trials on MBI for depression in family...
Translational Psychiatry
May 12, 2026
Linda Bryant, Laith Alexander, Sergio Mena et al.
Ketamine has demonstrated rapid antidepressant efficacy in treatment-resistant depression (TRD), but clinical decision-making is challenging due to variability in individual response. Current trial-and-error prescribing practices may expose patients to ineffective treatment and avoidable adverse effects, underscoring the need for reliable predictive tools to optimize treatment selection and...
Psychiatry Research
May 12, 2026
Isis Lunsky, Gilmar Gutierrez, Xena Wang et al.
Postpartum Depression (PPD) is a common condition with serious consequences for both mother and baby if left untreated. Currently, few effective strategies exist for prevention of PPD. Ketamine and Esketamine are rapid acting and potent antidepressants, and emerging evidence is showing promising results for PPD. This review searched the MEDLINE, CINAHL, PsycINFO, EMBASE, and Cochrane databases,...
Premier Journal of Neuroscience
May 11, 2026
Khadija Kamene
Background: Treatment-resistant depression (TRD) affects a significant proportion of individuals with major depressive disorder and remains difficult to manage with conventional treatments. Psychedelic-assisted therapies and neuromodulation have emerged as innovative interventions targeting neurobiological mechanisms beyond traditional antidepressant approaches. Objectives: This scoping review...
Research Square
May 11, 2026
Chloë K Walters, Sarentha Chetty, Thankhoe A Rants’o et al.
preprint
Abstract Background: Conventional pharmacotherapy for treatment-resistant depression (TRD) has been found to provide limited benefit in a subset of patients. Psilocybin‑assisted therapy has emerged as a promising modality due to its rapid‑acting antidepressant effects and favourable tolerability profile shown in early trials. Despite growing research interest in psilocybin‑assisted therapy the...